Skip to content

Real-world study of The efficacy and safety of The JAK inhibitor Baricitinib and Ritlecitinib for the treatment of severe alopecia areata

Real-world study of The efficacy and safety of The JAK inhibitor Baricitinib and Ritlecitinib for the treatment of severe alopecia areata

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114501
Enrollment
Unknown
Registered
2025-12-14
Start date
2025-04-29
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe alopecia areata

Interventions

Mild alopecia areata group:Topical application of minoxidil liniment and topical glucocorticoid preparations
Healthy control group:No intervention / Blank control
Severe alopecia areata group:Oral administration of JAK inhibitors for the treatment of baricitinib or ritlecitinib

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Healthy control group (aged 18-70 years), mild alopecia areata, and severe alopecia areata. Diagnosed alopecia areata cases without other causes of hair loss. 2.Healthy control group: Subjects who need surgery for simple skin tags and pigmented nevi, with the same gender and in the same age group as those in the case group, and who attend the dermatology outpatient department during the same period when the case group is enrolled. 3.Mild alopecia areata: Subjects with alopecia areata whose disease course is within 3 months, the number of alopecia areata patches is =50%, including alopecia totalis and alopecia universalis. The duration of the disease course is >= 6 months, and the patients are receiving treatment with baricitinib or ritlecitinib.

Exclusion criteria

Exclusion criteria: 1.Those with severe alopecia areata lasting less than 6 months; 2.Those who have received treatment with JAK inhibitors, systemic glucocorticoids, or other immunosuppressive agents within 3 months prior to enrollment. 3.Those who have received local glucocorticoid injection treatment for skin lesions within 1 month prior to enrollment.

Design outcomes

Primary

MeasureTime frame
The percentage change in the SALT score from the baseline at week 24;

Secondary

MeasureTime frame
The percentage of subjects whose absolute SALT score reaches = 20 once every 4 weeks.;The absolute change in the number of scalp hair follicles compared to the baseline (trichoscopy) once every 4 weeks;The percentage of subjects with SALT50, SALT75 and SALT90 once every 4 weeks.;Conduct the Severity of Alopecia Tool (SALT) scoring once every 4 weeks until the 24th week.;

Countries

China

Contacts

Public ContactXiaoyan Liu; Yinhua Wu

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

hzliuxiaoyan@126.com+86 139 5716 2809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026